Terms: = Ovarian cancer AND CTLA4, ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12 AND Prognosis
53 results:
1. Machine learning developed a fibroblast-related signature for predicting clinical outcome and drug sensitivity in ovarian cancer.
Fu W; Feng Q; Tao R
Medicine (Baltimore); 2024 Apr; 103(16):e37783. PubMed ID: 38640321
[TBL] [Abstract] [Full Text] [Related]
2. Machine learning developed a CD8
Chen R; Zheng Y; Fei C; Ye J; Fei H
Sci Rep; 2024 Mar; 14(1):5794. PubMed ID: 38461331
[TBL] [Abstract] [Full Text] [Related]
3. An exosome-derived lncRNA signature identified by machine learning associated with prognosis and biomarkers for immunotherapy in ovarian cancer.
Cui Y; Zhang W; Lu W; Feng Y; Wu X; Zhuo Z; Zhang D; Zhang Y
Front Immunol; 2024; 15():1228235. PubMed ID: 38404588
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic and immune infiltration features of disulfidptosis-related subtypes in breast cancer.
Chen S; Li X; Ao W
BMC Womens Health; 2024 Jan; 24(1):6. PubMed ID: 38166898
[TBL] [Abstract] [Full Text] [Related]
5. Machine Learning Developed a Programmed Cell Death Signature for Predicting prognosis, Ecosystem, and Drug Sensitivity in ovarian cancer.
Wang L; Chen X; Song L; Zou H
Anal Cell Pathol (Amst); 2023; 2023():7365503. PubMed ID: 37868825
[TBL] [Abstract] [Full Text] [Related]
6. Machine learning developed a PI3K/Akt pathway-related signature for predicting prognosis and drug sensitivity in ovarian cancer.
Han X; Yang L; Tian H; Ji Y
Aging (Albany NY); 2023 Oct; 15(20):11162-11183. PubMed ID: 37851341
[TBL] [Abstract] [Full Text] [Related]
7. Establishment and validation of an immune infiltration predictive model for ovarian cancer.
Song Z; Zhang J; Sun Y; Jiang Z; Liu X
BMC Med Genomics; 2023 Sep; 16(1):227. PubMed ID: 37759229
[TBL] [Abstract] [Full Text] [Related]
8. A Novel pyroptosis-related signature for predicting prognosis and evaluating tumor immune microenvironment in ovarian cancer.
Yang J; Wang C; Zhang Y; Cheng S; Xu Y; Wang Y
J Ovarian Res; 2023 Sep; 16(1):196. PubMed ID: 37730669
[TBL] [Abstract] [Full Text] [Related]
9. Tumor cell-expressed lipolysis-stimulated lipoprotein receptor negatively regulates T-cell function.
Funauchi M; Serada S; Hiramatsu K; Funajima E; Kanda M; Nagase Y; Nakagawa S; Ohkawara T; Fujimoto M; Suzuki Y; Ueda Y; Kimura T; Naka T
Int J Cancer; 2024 Feb; 154(3):425-433. PubMed ID: 37728485
[TBL] [Abstract] [Full Text] [Related]
10. Scoulerine promotes cytotoxicity and attenuates stemness in ovarian cancer by targeting PI3K/AKT/mTOR axis.
Wang F; Zhang Y; Pang R; Shi S; Wang R
Acta Pharm; 2023 Sep; 73(3):475-488. PubMed ID: 37708956
[TBL] [Abstract] [Full Text] [Related]
11. A methylation- and immune-related lncRNA signature to predict ovarian cancer outcome and uncover mechanisms of chemoresistance.
Chen L; Gao W; Lin L; Sha C; Li T; Chen Q; Wei H; Yang M; Xing J; Zhang M; Zhao S; Xu W; Li Y; Long L; Zhu X
J Ovarian Res; 2023 Sep; 16(1):186. PubMed ID: 37674251
[TBL] [Abstract] [Full Text] [Related]
12. Landscape of PCOS co-expression gene and its role in predicting prognosis and assisting immunotherapy in endometrial cancer.
Zhang Y; Hu Y; Yu J; Xie X; Jiang F; Wu C
J Ovarian Res; 2023 Jul; 16(1):129. PubMed ID: 37393293
[TBL] [Abstract] [Full Text] [Related]
13. Genetically engineered neural stem cells expressing cytosine deaminase and interferon-beta enhanced T cell-mediated antitumor immunity against gastric cancer in a humanized mouse model.
Choi Y; Lee HK; Ahn D; Nam MW; Go RE; Choi KC
Life Sci; 2023 Sep; 328():121866. PubMed ID: 37331506
[TBL] [Abstract] [Full Text] [Related]
14. A novel autophagy-related gene signature associated with prognosis and immune microenvironment in ovarian cancer.
Yang J; Wang C; Zhang Y; Cheng S; Wu M; Gu S; Xu S; Wu Y; Wang Y
J Ovarian Res; 2023 Apr; 16(1):86. PubMed ID: 37120633
[TBL] [Abstract] [Full Text] [Related]
15. Immune-Hot tumor features associated with recurrence in early-stage ovarian clear cell carcinoma.
Huang RY; Huang KJ; Chen KC; Hsiao SM; Tan TZ; Wu CJ; Hsu C; Chang WC; Pan CY; Sheu BC; Wei LH
Int J Cancer; 2023 May; 152(10):2174-2185. PubMed ID: 36629283
[TBL] [Abstract] [Full Text] [Related]
16. [Expression and significance of immune checkpoint B7-homolog 4 in endometrial cancer].
Zong LJ; Xiang Y; Yu SN; Lu ZH; Chen J; Huang WH
Zhonghua Fu Chan Ke Za Zhi; 2022 Dec; 57(12):921-931. PubMed ID: 36562226
[No Abstract] [Full Text] [Related]
17. Primary leiomyosarcoma of ovary: A rare malignancy as an incidental finding.
Raychaudhuri S; Sidam D; Jain M; Chawla R; Pujani M; Wadhwa R
Indian J Pathol Microbiol; 2022; 65(4):938-941. PubMed ID: 36308213
[TBL] [Abstract] [Full Text] [Related]
18. Exploration of the underlying biological differences and targets in ovarian cancer patients with diverse immunotherapy response.
Chen J; Chen S; Dai X; Ma L; Chen Y; Bian W; Sun Y
Front Immunol; 2022; 13():1007326. PubMed ID: 36189254
[TBL] [Abstract] [Full Text] [Related]
19. The analysis of hormonal status and vascular and cell proliferation in endometrioid endometrial adenocarcinomas.
Drocaş I; Crăiţoiu Ş; Stepan AE; Iliescu DG; Drocaş IA; Stepan MD
Rom J Morphol Embryol; 2022; 63(1):113-120. PubMed ID: 36074674
[TBL] [Abstract] [Full Text] [Related]
20. Construction of Metabolic Molecular Classification and Immune Characteristics for the prognosis Prediction of ovarian cancer.
Wang K; He H; Feng X
J Immunol Res; 2022; 2022():2359349. PubMed ID: 35800989
[TBL] [Abstract] [Full Text] [Related]
[Next]
